France opts for mRNA vaccines for second coronavirus shot


FILE PHOTO: A vial of the Oxford-AstraZeneca COVID-19 vaccine is pictured at the Foch hospital in Suresnes, near Paris, France, February 8, 2021. REUTERS/Benoit Tessier

PARIS (Reuters) - France's top health advisory body in charge of COVID-19 vaccines recommended on Friday that recipients of a first dose of the AstraZeneca shot who are under 55 should receive a second dose with a so-called messenger RNA vaccine.

Reuters reported on Thursday that the Haute Autorite de la Sante (HAS) had opted for the dose-mixing recommendation, which has not yet been evaluated in trials.

The French decision came after European drug regulators said on Wednesday there was a possible link between AstraZeneca's COVID-19 shot and a very small number of cases of rare blood clots.

Some countries had already suspended use of the AstraZeneca vaccine as a precaution, but most have resumed using the shot, although some have done so with age restrictions.

"This is a logical choice and one of security," Dominique Le Guludec, the head of the HAS, told reporters.

"Our approach is absolutely not to engage in a gigantic experimentation on the French population...We actually want to be cautious and not expose people to thromboembolic accidents, even though they are very rare," she said.

Two mRNA vaccines, one from Pfizer and BioNTech and one from Moderna, are approved for use in France.

mRNA vaccines prompt the human body to make a protein that mimics part of the virus, triggering an immune response, while AstraZeneca's shot uses a harmless, weakened version of a chimpanzee common-cold virus to deliver instructions to generate an immune response and prevent infection.

MORE STUDIES NEEDED

The HAS also called for real-world studies to assess the immune response triggered by the mixed vaccination scheme.

It said its decision was based on an immunisation strategy known as heterologous prime-boost, in which separate doses of different effective vaccines are used to confer protection.

The HAS said that while there is little data yet available on using different vaccines in a prime-boost strategy for COVID-19, animal studies and evidence from other disease areas is encouraging.

A member of the German vaccine commission, Marianne Roebl-Mathieu, said earlier this week she saw no immunological disadvantage for younger recipients of AstraZeneca's vaccine in getting a second dose of another vaccine.

In France, the HAS said on March 19 that only people aged 55 and over should get the AstraZeneca shot, which had already been given to more than 500,000 people as a first dose.

Germany was the first European country to recommend that people under 60 who have had a first AstraZeneca shot should receive a different vaccine as a second dose.

(Reporting by Sudip Kar-Gupta, Benoit Van Overstraeten; Writing by Matthias Blamont; Editing by Kate Kelland and Mark Heinrich)

Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 46
Cxense type: free
User access status: 3
   

Next In World

'Freedom' fiestas: Spaniards celebrate end of COVID curfew
Russia reports 8,419 new COVID-19 cases, 334 deaths
UK's Gove refuses to say how London will handle Scottish independence drive
Syria says fire erupts in main Homs refinery - state media
Ethiopian Orthodox Church head says genocide is taking place in Tigray
Lukashenko signs decree to amend emergency transfer of power - Belta
Chinese rocket debris lands in Indian Ocean, draws criticism from NASA
India's daily COVID-19 deaths near record, calls for nationwide lockdown mount
Germany's confirmed coronavirus cases rise by 12,656 - RKI
Afghan school blast toll rises to 58, families bury victims

Stories You'll Enjoy


Vouchers